Effect of Recrystallization Technique on Oral Bioavailability of Valsartan
Valsartan (VAL) is a widely prescribed anti-hypertensive agent with angiotensin II type I receptor antagonistic activity. VAL belongs to BCS class II having a low and variable oral bioavailability (10-35%) and its absorption is dissolution rate limited. Recrystallization of VAL from different organic solvents improved VAL aqueous solubility and thereby in vitro dissolution properties. In this investigation in vivo oral bioavailability (BA) of VAL and its recrystallized products with methanol and ethanol (VMET and VETH respectively) solvents was evaluated in male Wistar rats. Also, a rapid, economical and reliable RP-HPLC-PDA method was developed for the estimation of VAL in rat plasma samples and validated according to ICH guidelines. Chromatographic separation was achieved on an Agilent eclipse C18 column (150×4.6mm, 5µ) with a mobile phase composition of 10mM ammonium acetate: acetonitrile (75:25%v/v) at a flow rate of 1.2 mL/min. The retention time of VAL was found to be 2.9 min and showed good linearity (R2>0.996) in the selected concentration range of 0.5-25µg/mL. A 2.9, 2.8 folds increase in Cmax and a relative bioavailability of 320, 305% was observed with VMET and VETH respectively, when compared to that of untreated VAL. Thus it can be inferred that recrystallization is easy and economical technique for enhancing the pharmaceutical properties like solubility, dissolution properties and oral BA of poorly water soluble drugs like VAL.
Keywords: Bioanalytical method, Bioavailability, Male Wistar rats, Valsartan, Recrystallization
2. Flesch G, Lloyd P, Müller P.H. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist. Eur J Clin Pharmacol., 1997; 52:115-120. https://doi.org/10.1007/s002280050259
3. Nadeem S, Asif H, Lakshita C, Shamsher M.A, Mitra M, Parminder S.B. Pharmacological and Pharmaceutical Profile of Valsartan: A Review. Journal of Applied Pharmaceutical Science, 2011; 01 (04):12-19.
4. Dixit A.R, Rajput SJ, Patel S.G. Preparation and Bioavailability Assessment of SMEDDS Containing Valsartan. AAPS PharmSciTech, 2010;11(1):314-321. https://doi.org/10.1208/s12249-010-9385-0
5. Yana Y.D, Sunga J.H, Kima K.K, Kimb D.W, Kima J.O, Leec B.J, Yonga C.S, Choi H.G. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. International Journal of Pharmaceutics, 2012; 422(1-2):202-210. https://doi.org/10.1016/j.ijpharm.2011.10.053
6. Qiuping M, Hongrui S, Erxi C, Xin Z, Tongying J, Changshan S, Siling W. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: Influence of particle size and crystalline state. International Journal of Pharmaceutics, 2012; 441 (1-2):75-81. https://doi.org/10.1016/j.ijpharm.2012.12.025
7. De Matos Jensen C.E, Dos Santos R.A.S, Denadai A.M.L, Santos C.F.F, Braga A.N.G; Sinisterra R.D. Pharmaceutical Composition of Valsartan: β-Cyclodextrin: Physico-chemical characterization and anti-hypertensive evaluation. Molecules, 2010; 15:4067-4084. https://doi.org/10.3390/molecules15064067
8. Amit C, Upendra N, Neha G, Sharma V.K, Khosa R.L. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. Journal of Advanced Pharmacy Education & Research, 2012; 2(1):32-67.
9. Nalluri B.N, Ramya K.M, Rao T.P, Peter A.C. Effect of Recrystallization on the Pharmaceutical Properties of Valsartan for Improved Therapeutic Efficacy. Journal of Applied Pharmaceutical Science, 2012; 2(10):126-132. https://doi.org/10.7324/JAPS.2012.21025
10. Samya M.E, Osama H.A, Mahmoud A.O, Sayed M.D. Development and Validation of HPLC Method for Simultaneous Determination of Amlodipine, Valsartan, Hydrochlorothiazide in Dosage Form and Spiked Human Plasma. American Journal of Analytical Chemistry, 2012; 3:422-430. https://doi.org/10.4236/ajac.2012.36055
11. Bhatia M.S, Kokil S.U. Determination and validation of valsartan and its degradation products by isocratic HPLC. J. Chem. Metrl., 2009; (3)1:1-12.
12. Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. Journal of Chromatography B, 2006; 832(1):169-172. https://doi.org/10.1016/j.jchromb.2005.12.035
13. Nozomu K, Hiroto K, Hisanori H, Miyuki N, Makoto T, Ryosei K, Yusuke N, Naoki M. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2007; 43(5):1769-1774. https://doi.org/10.1016/j.jpba.2006.12.030
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use. Validation of Text and Methodology Q2 (R1), 2005
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).